October 01, 2015
Kite Pharma Announces Peer-Reviewed Publication of T Cell Receptor Based Product Candidate to Treat HPV-Associated Cancers
- TCR product candidate targeting human papillomavirus (HPV)-16 E6 selectively kills cervical and head and neck cancer cells
- Phase 1/2 clinical trial of the HPV-16 E6 TCR is enrolling patients at the
"HPV-16 E6 is a viral oncogene that is causally associated with cervical and other HPV-related cancers. Because E6 protein is expressed in cancer cells and absent in normal, healthy tissues, a TCR product candidate with high selectivity for this oncogene has the potential to become a novel cellular therapy directed against HPV-16 positive cancers," commented
"HPV infection, responsible for diverse urogenital cancers and the fastest-growing type of cancers of the head and neck, represents an area of compelling unmet medical needs for patients," stated Arie Belldegrun, M.D., FACS, Kite's President and Chief Executive Officer. "Peer-reviewed publications, such as in AACR's Clinical Cancer Research, continue to add significant validation for our broad, advancing pipeline of candidates to treat patients with solid tumors."
About HPV-Associated Cancers
There were over 500,000 new cases of and 275,000 deaths attributable to cervical cancer worldwide in 2008.1 Human papillomavirus (HPV) is the most common viral infection of the reproductive tract, and HPV-16 is believed to cause about 50-60% of cervical cancers. HPV-16 is also implicated in additional urogenital and head and neck cancer types,2 and is believed to cause 90% of HPV-mediated oropharyngeal cancers and the majority of HPV-mediated anal, penile, vaginal and vulvar cancers.
About TCR-based Immunotherapy
Kite's broadly enabling eACT™ technology platform allows a patient's T cells to be genetically modified to express cancer-targeting receptors, including TCRs. Engineered TCR T cells express alpha and beta chains of the T cell receptor, which recognize and bind to MHC-presented tumor antigens. Once modified, the T cells can traffic directly to tumor sites and become activated upon engagement with the target tumor antigen, selectively eradicating the tumor cells.
This press release contains forward-looking statements for purposes of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The press release may, in some cases, use terms such as "predicts," "believes," "potential," "proposed," "continue," "estimates," "anticipates," "expects," "plans," "intends," "may," "could," "might," "will," "should" or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. Forward-looking statements include statements regarding intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things: the success of the NCI's ongoing HPV TCR product candidate clinical trial and obtaining results from the trial, and the ability and timing of filing a Kite IND on a HPV TCR product candidate. Various factors may cause differences between Kite's expectations and actual results as discussed in greater detail in Kite's filings with the
CONTACT: Kite Contacts:Source:
Cynthia M. ButittaChief Financial Officer and Chief Operating Officer 310-824-9999 For Media: Justin JacksonFor Investor Inquiries: Lisa Burns Burns McClellan212-213-0006 firstname.lastname@example.org email@example.com
News Provided by Acquire Media